OTC drugs that could go on retail shelves include those used for the treatment of gingivitis, paracetamol tablets 500 mg, ...

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

Kindeva manufactures nasal-based drugs. It celebrated the opening of its new building and recent expansion Thursday.

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

Kindeva Drug Delivery, located off of Newtown Pike and Citation Boulevard, specializes in manufacturing life-saving ...

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency. The drug – a new dry powder ...

A budget proposal from President Donald Trump’s administration would cut a federal grant that provides $56 million annually ...

The studies showed that the nasal powder had rapid absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels. The drug was well tolerated when used long-term ...